Before initiating treatment, a comprehensive medical history review and consultation with a qualified healthcare provider remain essential steps
In clinical trials, treatment with tirzepatide produced superior weight loss and glycemic control compared to GLP-1RAs 3,17 , suggesting that agonism at both the GIPR and GLP-1R is beneficial in humans with type 2 diabetes
In some cases, possession or distribution of these peptides without proper authorization may result in legal consequences
The pathological association between nutrition and OA Obesity and OA: intertwined pathways of inflammation, mechanics, and diet Obesity is a critical risk factor for OA, driven by a synergy of mechanical overload and adipose tissue-mediated systemic inflammation
Combining them does not necessarily increase the risk of side effects, but it may make it harder to determine which product is causing a specific symptom if one arises
demonstrated that the administration of tirzepatide (15 mg) significantly improves the clamp disposition index from baseline to week 28 of treatment compared to semaglutide or a placebo
